Kenji Yasukawa is stepping down as chief executive of Japanese pharma group Astellas, to be succeeded by Naoki Okamura – currently chief strategy officer – on 1st April.
Pfizer reaped the rewards of its COVID-19 vaccines and therapeutics in 2022, but there are already signs of falling demand that looks likely to get significantly worse in
Sio Gene Therapies' litany of clinical disappointments over the last few years has finally led to the demise of the biotech, formerly known as Axovant and one of the 'vant' companies origin
Elizabeth Holmes, the founder and former chief executive of blood testing biotech Theranos, has been sentenced after being convicted of defrauding investors in the company earlier this year
Clovis Oncology has said it may not have enough cash to fund continuing operations beyond January next year, as it struggles to reverse a decline in sales of PARP inhibitor Rubraca.
In its first set of quarterly results since it separated from its consumer health business, GSK has exceeded analysts' estimates, with a healthy rise in revenue and profit driven by shingle